{'_data': [['Unknown',
            [['Blood',
              u'Very rarely, thrombocytopenia. Post-marketing Safety Study In a post-marketing safety study, a total of 12,523 individuals 2 through 17 years of age received 1 or 2 doses of VAQTA. There was no serious, vaccine-related, adverse event identified. There was no nonserious, vaccine-related, adverse event resulting in outpatient visits.']]]],
 '_pages': [5, 7],
 u'_rank': 1,
 u'_type': u'LSFU'}